Fortress Biotech Inc (FBIO)

$3.73 +0.43 (13.03%)
Market Cap 109.62M
Revenue (ttm) 63.26M
Net Income (ttm) 6.82M
EPS (ttm) N/A
PE Ratio 1.46
Forward PE N/A
Profit Margin 10.78%
Debt to Equity Ratio 0.18
Volume 1,243,700
Avg Vol 500,718
Day's Range N/A - N/A
Shares Out 33.22M
Stochastic %K 98%
Beta 1.21
Analysts Sell
Price Target $11.00

Company Profile

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular m...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States
KeepYourDayJob
KeepYourDayJob Jul. 15 at 12:27 PM
$FBIO shorts are going to press hard to keep it off momentum traders radars!
0 · Reply
StockScanners
StockScanners Jul. 15 at 4:43 AM
$FBIO keep watch if this holds above 3.61
0 · Reply
drose0527
drose0527 Jul. 14 at 11:18 PM
$FBIO nice strong close! I would expect a pull back off of the 13% run today I think we will fall back to test the 60 day MA over the next 3 days and mostly 3.10-3.15. As it has shown repeatedly it touches to end of our channel and sells off with every touch today we actually pushed up channel ceiling trajectory and I would believe this needs to cool off as it has ran 31% in 5 days going almost straight up I would look for a very light volume day tomorrow and very much profit taking right here we could lose 5-7% off of our 13% run today
1 · Reply
ggp110
ggp110 Jul. 14 at 10:40 PM
$FBIO $FBIO SHORT Squeeze incoming!
0 · Reply
buymoremakemore
buymoremakemore Jul. 14 at 8:18 PM
$FBIO i really hope wasnt that fortress invetsments news. I dont think it was. Yesterday this hit $3.40 range but market was weak with macro and it pulled back. Now inflation has cooled abit, and biotech loves that for M&A and other reasons. I think this was a legit breakout.
0 · Reply
KeepYourDayJob
KeepYourDayJob Jul. 14 at 8:10 PM
$FBIO this aged well. Possible news?
0 · Reply
TradeX_
TradeX_ Jul. 14 at 8:00 PM
Looks like BMGL might be the next 800% runner. Crazy market! Every micro float ticker has been going parabolic this month. Would not be surprised if they send BMGL up now. BMGL starting to make its move now! Only 750k shares outstanding! 💎 $ABCL $FBIO $TGTX 0s
3 · Reply
KeepYourDayJob
KeepYourDayJob Jul. 14 at 8:00 PM
$FBIO Webull continuously confuses it with Fortess real estate as well but everytime it seems to help the stock. Weak news scraping algos?
0 · Reply
TB83Stock
TB83Stock Jul. 14 at 7:53 PM
$FBIO AH News??
0 · Reply
wolfman1271
wolfman1271 Jul. 14 at 7:33 PM
$FBIO Almost 1 mill in volume, lets get eyes on this!!
0 · Reply
Latest News on FBIO
Fortress Biotech Slides: Investor presentation

Jul 1, 2026, 8:00 AM EDT - 14 days ago

Fortress Biotech Slides: Investor presentation

Fortress Biotech Transcript: AGM 2026

Jun 17, 2026, 10:00 AM EDT - 27 days ago

Fortress Biotech Transcript: AGM 2026

Fortress Biotech Slides: Corporate presentation

Jun 8, 2026, 7:00 AM EDT - 5 weeks ago

Fortress Biotech Slides: Corporate presentation

Fortress Biotech Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 20, 2026, 12:20 PM EDT - 7 weeks ago

Fortress Biotech Transcript: A.G.P.'s Annual Virtual Healthcare Conference

Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference

May 19, 2026, 4:45 PM EDT - 2 months ago

Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference

DERM

Fortress Biotech price target raised to $5 from $4.50 at Alliance Global

2026-05-18T13:00:31.000Z - 2 months ago

Fortress Biotech price target raised to $5 from $4.50 at Alliance Global

DERM

Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference

May 18, 2026, 8:30 AM EDT - 2 months ago

Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference

FBIOP

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026, 4:10 PM EDT - 2 months ago

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

FBIOP

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 13, 2026, 4:01 PM EDT - 2 months ago

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

DERM

Fortress Biotech Earnings Call Transcript: Q1 2026

May 13, 2026, 4:00 PM EDT - 2 months ago

Fortress Biotech Earnings Call Transcript: Q1 2026

Fortress Biotech Quarterly report: Q1 2026

May 13, 2026, 4:00 PM EDT - 2 months ago

Fortress Biotech Quarterly report: Q1 2026

Fortress Biotech Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 2 months ago

Fortress Biotech Earnings release: Q1 2026

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

May 6, 2026, 4:01 PM EDT - 2 months ago

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

DERM

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

May 4, 2026, 8:30 AM EDT - 2 months ago

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

FBIOP

Fortress Biotech Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Fortress Biotech Proxy statement: Proxy filing

Fortress Biotech Proxy statement: Proxy filing

Apr 27, 2026, 7:00 AM EDT - 2 months ago

Fortress Biotech Proxy statement: Proxy filing

Fortress Biotech Slides: Corporate presentation

Apr 22, 2026, 7:00 AM EDT - 3 months ago

Fortress Biotech Slides: Corporate presentation

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Apr 21, 2026, 8:30 AM EDT - 3 months ago

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

DERM

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Mar 31, 2026, 4:05 PM EDT - 3 months ago

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

FBIOP

Fortress Biotech Earnings release: Q4 2025

Mar 31, 2026, 4:00 PM EDT - 3 months ago

Fortress Biotech Earnings release: Q4 2025

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Mar 30, 2026, 4:05 PM EDT - 3 months ago

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Mar 25, 2026, 4:01 PM EDT - 3 months ago

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

DERM

Fortress Biotech Slides: Corporate presentation

Mar 19, 2026, 7:00 AM EDT - 4 months ago

Fortress Biotech Slides: Corporate presentation

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Mar 18, 2026, 8:30 AM EDT - 4 months ago

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

DERM

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Feb 23, 2026, 9:24 AM EST - 5 months ago

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

FBIOP

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

2026-02-23T13:53:18.000Z - 5 months ago

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Feb 23, 2026, 8:30 AM EST - 5 months ago

Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

FBIOP

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

Feb 23, 2026, 8:00 AM EST - 5 months ago

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

Fortress Biotech, Cyprium announce FDA approval of ZYCUBO

2026-01-13T12:50:22.000Z - 6 months ago

Fortress Biotech, Cyprium announce FDA approval of ZYCUBO

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Jan 13, 2026, 7:45 AM EST - 6 months ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

FBIOP

Fortress Biotech Registration statement: Registration Filing

Dec 16, 2025, 7:00 AM EST - 7 months ago

Fortress Biotech Registration statement: Registration Filing

Fortress Biotech files to sell 600,000 shares of common stock for holders

2025-12-16T11:11:34.000Z - 7 months ago

Fortress Biotech files to sell 600,000 shares of common stock for holders

Fortress Biotech, Cyprium announce FDA acceptance of CUTX-101 NDA resubmission

2025-12-15T13:10:58.000Z - 7 months ago

Fortress Biotech, Cyprium announce FDA acceptance of CUTX-101 NDA resubmission

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Dec 15, 2025, 8:00 AM EST - 7 months ago

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Dec 10, 2025, 8:30 AM EST - 7 months ago

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

DERM

Fortress Biotech price target raised to $4.50 from $4 at Alliance Global

2025-11-19T12:15:57.000Z - 8 months ago

Fortress Biotech price target raised to $4.50 from $4 at Alliance Global

Fortress Biotech reports Q3 EPS 11c vs (76c) last year

2025-11-14T13:40:48.000Z - 8 months ago

Fortress Biotech reports Q3 EPS 11c vs (76c) last year

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 14, 2025, 8:30 AM EST - 8 months ago

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Fortress Biotech Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Fortress Biotech Earnings Call Transcript: Q3 2025

Fortress Biotech Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Fortress Biotech Quarterly report: Q3 2025

Fortress Biotech Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Fortress Biotech Earnings release: Q3 2025

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 12, 2025, 4:01 PM EST - 8 months ago

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Nov 6, 2025, 7:00 AM EST - 8 months ago

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

AXSM

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Nov 5, 2025, 8:30 AM EST - 8 months ago

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

DERM

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

Oct 24, 2025, 8:30 AM EDT - 9 months ago

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

DERM

Fortress subsidiary announces Crystalys dosed patient in study of dotinurad

2025-10-21T12:35:27.000Z - 9 months ago

Fortress subsidiary announces Crystalys dosed patient in study of dotinurad

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout

Oct 21, 2025, 8:30 AM EDT - 9 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout

FBIOP

Journey Medical Corporation to Participate in October 2025 Investor Conferences

Oct 8, 2025, 8:30 AM EDT - 10 months ago

Journey Medical Corporation to Participate in October 2025 Investor Conferences

DERM

Fortress Biotech Investigated by the Portnoy Law Firm

Oct 1, 2025, 3:45 PM EDT - 10 months ago

Fortress Biotech Investigated by the Portnoy Law Firm

Why Is Fortress Biotech Stock (FBIO) Down 30% Today?

2025-10-01T13:07:24.000Z - 10 months ago

Why Is Fortress Biotech Stock (FBIO) Down 30% Today?

Fortress Biotech, Urica announces Crystalys’ $205M Series A financing

2025-10-01T12:30:16.000Z - 10 months ago

Fortress Biotech, Urica announces Crystalys’ $205M Series A financing

Fortress Biotech, Cyprium receive CRL related to NDA for CUTX-101

2025-10-01T12:11:28.000Z - 10 months ago

Fortress Biotech, Cyprium receive CRL related to NDA for CUTX-101

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

Oct 1, 2025, 8:05 AM EDT - 10 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

FBIOP

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

Oct 1, 2025, 8:00 AM EDT - 10 months ago

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

FBIOP

Journey Medical Corporation to Participate in September 2025 Investor Conferences

Sep 3, 2025, 8:30 AM EDT - 11 months ago

Journey Medical Corporation to Participate in September 2025 Investor Conferences

DERM

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 11 months ago

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FBIOP

Fortress Biotech price target lowered to $17 from $26 at H.C. Wainwright

2025-08-21T10:20:36.000Z - 11 months ago

Fortress Biotech price target lowered to $17 from $26 at H.C. Wainwright

Fortress Biotech price target lowered to $12 from $15 at Roth Capital

2025-08-19T12:15:37.000Z - 11 months ago

Fortress Biotech price target lowered to $12 from $15 at Roth Capital

Journey Medical Corporation to Present at the Emerging Growth Conference

Aug 18, 2025, 8:30 AM EDT - 11 months ago

Journey Medical Corporation to Present at the Emerging Growth Conference

DERM

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 14, 2025, 4:05 PM EDT - 11 months ago

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 12, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Fortress Biotech Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Fortress Biotech Quarterly report: Q2 2025

Fortress Biotech Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Fortress Biotech Earnings release: Q2 2025

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

DERM

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

Aug 5, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

DERM

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Jul 14, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

DERM

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

DERM

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

Jun 20, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

DERM

Fortress Biotech Transcript: AGM 2025

Jun 17, 2025, 10:00 AM EDT - 1 year ago

Fortress Biotech Transcript: AGM 2025

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

Jun 9, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

DERM

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

May 30, 2025, 10:47 AM EDT - 1 year ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIOP

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 15, 2025, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Fortress Biotech Quarterly report: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

Fortress Biotech Quarterly report: Q1 2025

Fortress Biotech Earnings release: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

Fortress Biotech Earnings release: Q1 2025

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 14, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

May 13, 2025, 4:15 PM EDT - 1 year ago

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

CKPT

Fortress Biotech management to meet virtually with Roth MKM

2025-05-08T15:45:41.000Z - 1 year ago

Fortress Biotech management to meet virtually with Roth MKM

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

May 7, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

DERM

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

FBIOP

Fortress Biotech Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech Proxy statement: Proxy Filing

Fortress Biotech Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech Proxy statement: Proxy Filing

Fortress Biotech Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech Proxy statement: Proxy Filing

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

Apr 1, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

DERM

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

CKPT

Fortress Biotech Annual report: Q4 2024

Mar 26, 2025, 4:30 PM EDT - 1 year ago

Fortress Biotech Annual report: Q4 2024

Fortress Biotech Earnings release: Q4 2024

Mar 26, 2025, 4:30 PM EDT - 1 year ago

Fortress Biotech Earnings release: Q4 2024

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

DERM

Fortress Biotech, Partex enter collaboration for asset identification

2025-03-17T13:07:15.000Z - 1 year ago

Fortress Biotech, Partex enter collaboration for asset identification

Fortress Biotech, Partex enter collaboration for asset identification, evaluatio

2025-03-17T13:00:50.000Z - 1 year ago

Fortress Biotech, Partex enter collaboration for asset identification, evaluatio

KeepYourDayJob
KeepYourDayJob Jul. 15 at 12:27 PM
$FBIO shorts are going to press hard to keep it off momentum traders radars!
0 · Reply
StockScanners
StockScanners Jul. 15 at 4:43 AM
$FBIO keep watch if this holds above 3.61
0 · Reply
drose0527
drose0527 Jul. 14 at 11:18 PM
$FBIO nice strong close! I would expect a pull back off of the 13% run today I think we will fall back to test the 60 day MA over the next 3 days and mostly 3.10-3.15. As it has shown repeatedly it touches to end of our channel and sells off with every touch today we actually pushed up channel ceiling trajectory and I would believe this needs to cool off as it has ran 31% in 5 days going almost straight up I would look for a very light volume day tomorrow and very much profit taking right here we could lose 5-7% off of our 13% run today
1 · Reply
ggp110
ggp110 Jul. 14 at 10:40 PM
$FBIO $FBIO SHORT Squeeze incoming!
0 · Reply
buymoremakemore
buymoremakemore Jul. 14 at 8:18 PM
$FBIO i really hope wasnt that fortress invetsments news. I dont think it was. Yesterday this hit $3.40 range but market was weak with macro and it pulled back. Now inflation has cooled abit, and biotech loves that for M&A and other reasons. I think this was a legit breakout.
0 · Reply
KeepYourDayJob
KeepYourDayJob Jul. 14 at 8:10 PM
$FBIO this aged well. Possible news?
0 · Reply
TradeX_
TradeX_ Jul. 14 at 8:00 PM
Looks like BMGL might be the next 800% runner. Crazy market! Every micro float ticker has been going parabolic this month. Would not be surprised if they send BMGL up now. BMGL starting to make its move now! Only 750k shares outstanding! 💎 $ABCL $FBIO $TGTX 0s
3 · Reply
KeepYourDayJob
KeepYourDayJob Jul. 14 at 8:00 PM
$FBIO Webull continuously confuses it with Fortess real estate as well but everytime it seems to help the stock. Weak news scraping algos?
0 · Reply
TB83Stock
TB83Stock Jul. 14 at 7:53 PM
$FBIO AH News??
0 · Reply
wolfman1271
wolfman1271 Jul. 14 at 7:33 PM
$FBIO Almost 1 mill in volume, lets get eyes on this!!
0 · Reply
Robertsylvan
Robertsylvan Jul. 14 at 7:14 PM
$FBIO I don’t think fortress investment group is related to FBIO…but correct if I am wrong.
1 · Reply
KeepYourDayJob
KeepYourDayJob Jul. 14 at 7:10 PM
$FBIO power hour
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 14 at 6:56 PM
$FBIO yep
0 · Reply
urban979
urban979 Jul. 14 at 6:30 PM
$FBIO 5$+ pls
0 · Reply
Chaka1647
Chaka1647 Jul. 14 at 6:09 PM
Another day where $FBIO flying on strong volume yet $FBIOP languishing Wonder what is going on
2 · Reply
braves1983
braves1983 Jul. 14 at 6:02 PM
$FBIO I like it. Now just keep going and stay green
0 · Reply
drose0527
drose0527 Jul. 14 at 5:59 PM
$FBIO looks like she wants to run again
0 · Reply
KeepYourDayJob
KeepYourDayJob Jul. 14 at 5:32 PM
$FBIO https://sg.finance.yahoo.com/news/celyad-oncology-announces-500-000-073200408.html
2 · Reply
Oscarca
Oscarca Jul. 14 at 4:41 PM
$FBIO pushing that $4
0 · Reply
drose0527
drose0527 Jul. 14 at 4:41 PM
$FBIO might hit 3.64 today
0 · Reply
buymoremakemore
buymoremakemore Jul. 14 at 3:04 PM
$FBIO Time for shorts to cover. 23% gain in Emrosi prescriptions from Q1 to Q2 means more revenue, especially since more time has passed in insurance reimbursement talks with PBMs and DERM contracting with the 3rd GPO in the middle of Q2.
1 · Reply
KeepYourDayJob
KeepYourDayJob Jul. 14 at 2:38 PM
$FBIO Wants to run so bad
0 · Reply